>Marburg?!?
https://nypost.com/2021/12/13/35-hospitalized-in-florida-with-after-smoking-synthetic-spice/
35 hospitalized in Florida with severe bleeding after smoking synthetic ‘spice’
By Patrick Reilly
December 13, 2021
>Marburg?!?
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
December 2, 2021
December 2, 2021·11 min read
In this article:
SNGX
-6.53%
Explore the topics mentioned in this article
Thermostabilized single vial vaccine targeting Sudan and Marburg filovirusesprotects 100% of non-human primates against lethal Sudan ebolavirus challenge
PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus (SUDV) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration with the University of Hawaiʻi at Mānoa (UHM), demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the vaccine platform, and its potential role in theUS government's initiative for pandemic preparedness. This same heat stable vaccine platform has also been applied to the development of a COVID-19 vaccine, CiVax™, which the Company anticipates testing against the new omicron variant, having shown immunogenicity against previous variants including delta.
The antigens and adjuvants used in this study have been previously shown to protect NHPs from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs. Lyophilization of the antigens within monovalent vaccine formulations has also been demonstrated to thermostabilize the antigens at temperatures as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to 12 weeks, enabling storage at ambient temperature. No currently approved lyophilized vaccine that contains adjuvant is presented in a single vial format and there are few reports of successfully using nano-emulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s) and a nano-emulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity. This most recent milestone confirms that in the context of lethal challenge with Sudan ebolavirus, complete protection is maintained with the thermostabilized formulation.
more at sauce
>Marburg?!?
https://apnews.com/press-release/NewMediaWire/coronavirus-pandemic-technology-science-business-health-2de119b6271e8bf0edab16bcc17572f9
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
GeoVax, Inc.
December 3, 2021
Atlanta, GA - ( NewMediaWire ) - December 03, 2021 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developinghuman vaccines and cancer immunotherapies, presented data from ongoing studies of itsinvestigational vaccines against hemorrhagic fevers(Sudan, Ebola, & Marburg) at the recent World Vaccine & Immunotherapy Congress, held November 30 – December 2 in San Diego, California. The presentation, titled “Design and Evaluation of Vaccines Against Hemorrhagic Fevers using the MVA-VLP Platform”, was delivered by Mary Hauser, PhD, GeoVax Senior Scientist.
In her talk,Dr. Hauser discussed the preclinical efficacy of GeoVax’s vaccines against Sudan (SUDV) and Marburg (MARV) viruses, twohighly virulent filovirus strains that cause hemorrhagic fever. Using the GV-MVA-VLPTM platform, vaccines were engineered to express two proteins from the target pathogen resulting in the formation of virus-like particles that retain the native virus structure. Recent studies in lethal challenge guinea pig models demonstrated that GeoVax vaccines MVA-VLP-SUDV and MVA-VLP-MARV conferred 100% protection from death. These vaccines were subsequently evaluated in a rigorous cynomolgus macaque infectious challenge model. Vaccination protected nonhuman primates from viremia, weight loss and death following challenge with a dose of Sudan or Marburg virus that is lethal in nonvaccinated animals. Evaluation of immune responses following vaccination demonstrated presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. Dr. Hauser’s presentation is available on GeoVax’s website at www.geovax.com/investors/events.